| Abstract: | 許多研究指出糖尿病與氧化壓力及發炎反應有關；輔酶Q10是很好的抗氧化與抗發炎物質。本研究目的為給予第2型糖尿病人水溶性還原型輔酶Q10補充劑（100 mg/d）對其血糖、血脂、氧化壓力及發炎指標之影響。本研究為雙盲、隨機、安慰劑對照組試驗。47位第2型糖尿病人隨機分派至安慰劑（n = 23）及輔酶Q10組（n = 24），介入12週。研究期間測量其血漿輔酶Q10濃度、維生素A、β-胡蘿蔔素、維生素E、維生素B12、血糖狀態（空腹血糖、糖化血色素、胰島素、C-胜肽、HOMA-IR、HOMA-B、QUICKI）、血脂狀態（TC、TG、LDL-C、HDL-C）、氧化壓力指標（ox-LDL-C、MDA）、抗氧化酵素活性（SOD、CAT、GPx）及發炎指標（hs-CRP、IL-6）濃度。結果顯示：介入12週後，輔酶Q10組之糖化血色素顯著低於介入前（p = 0.03）；總降血糖藥物分數（1.12 +- 1.07 vs. 1.40 +- 0.71，p = 0.03）顯著低於安慰劑組；雖然輔酶Q10介入對血脂濃度無顯著影響，但值得注意的是，安慰劑組之HDL-C濃度顯著低於介入前（p < 0.01）。輔酶Q10介入後顯著提升受試者抗氧化酵素活性（CAT，p < 0.01；GPx，p = 0.03）；輔酶Q10組之發炎指標（hs-CRP）濃度顯著低於安慰劑組（p < 0.05）。另介入後血漿輔酶Q10濃度與胰島素濃度、HOMA-IR及發炎指標（hs-CRP）濃度呈顯著之負相關。因此，我們建議第2型糖尿病人可藉由補充水溶性還原型輔酶Q10營養補充劑（100 mg/d）提升其抗氧化力，進而輔助調節血糖（糖化血色素）、維持HDL-C濃度及降低發炎反應（hs-CRP）。Diabetes mellitus has been reported to be associated with oxidative stress and inflammation status. Studies have indicated that coenzyme Q10 is a lipophic antioxidant and anti-inflammation agent. The purpose of this study was to examine the levels of blood glucose, lipid profiles, oxidative stress, and inflammation in patients with type 2 diabetes with water-soluable coenzyme Q10 supplementation (100 mg/d). This study was designed as a randomized, double-blind, placebo-controlled trial. Forty-seven participants was randomly assignedto placebo (n = 23) or coenzyme Q10 (n = 24) group. Intervention for 12 weeks. Plasma coenzyme Q10, vitamin A, β-carotene,vitamin E, vitamin B12, glucose homeostasis parameters (fasting glucose, HbA1C, insulin, C-peptide, HOMA-IR, HOMA-B, QUICKI), lipid profiles (TC, TG, LDL-C, HDL-C), anti-oxidative enzymes activity (SOD, CAT, GPx), oxidative stress (ox-LDL-C, MDA), and inflammatory markers (hs-CRP, IL-6) were measured during the study. After 12 week supplementation, HbA1C was significantly decreased in coenzyme Q10 group (p = 0.03) and subjects in the coenzyme Q10 group had significantly lower medicine effect score than the placebo group (1.12 +- 1.07 vs. 1.40 +- 0.71, p = 0.03). Coenzyme Q10 supplementation had no effect on the level of lipid profiles, however, the levelof HDL-C was significantly decreased (p < 0.01) in the placebo group after 12 weeks intervention. The values of antioxidative enzymes activity (CAT, p < 0.01; GPx, p = 0.03) were significantly increased after supplementation. Subjects in the coenzyme Q10 had significantly lowerlevel of hs-CRP than those in the placebo group (p < 0.05). In addition, coenzyme Q10 level was significantly negative correlated with the level of insulin, HOMA-IR, and the level ofhs-CRP after supplementation. Therefore, we suggested that patients with type 2 diabetes could use water-soluble coenzyme Q10 supplementation (100 mg/d) to increase their antioxidative capacity; thereby modulating blood glucose (HbA1C), maintaining HDL-C level, and decreasing inflammation status (hs-CRP). |
